Geron Corporation (GERN)
- Previous Close
3.8300 - Open
3.8700 - Bid 3.9700 x 2600
- Ask 4.0000 x 2600
- Day's Range
3.7600 - 4.0200 - 52 Week Range
1.6400 - 4.3000 - Volume
16,351,557 - Avg. Volume
12,935,311 - Market Cap (intraday)
2.367B - Beta (5Y Monthly) 0.55
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3400 - Earnings Date Aug 1, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.07
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
www.geron.comRecent News: GERN
Performance Overview: GERN
Trailing total returns as of 6/4/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GERN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GERN
Valuation Measures
Market Cap
2.37B
Enterprise Value
2.01B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.49k
Price/Book (mrq)
6.86
Enterprise Value/Revenue
3.87k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-28.94%
Return on Equity (ttm)
-60.04%
Revenue (ttm)
520k
Net Income Avi to Common (ttm)
-201.4M
Diluted EPS (ttm)
-0.3400
Balance Sheet and Cash Flow
Total Cash (mrq)
443.05M
Total Debt/Equity (mrq)
25.09%
Levered Free Cash Flow (ttm)
-108.98M